The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study.
Abstract
[BACKGROUND] Breast augmentation can result in significant postsurgical pain.
[OBJECTIVES] The authors evaluate the extent and duration of analgesia achieved with extended-release DepoFoam bupivacaine (Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty under general anesthesia.
[METHODS] In this randomized, multicenter, double-blind study, patients received a single dose of DepoFoam bupivacaine 600 mg or bupivacaine HCl 200 mg divided into the implant pockets at the conclusion of surgery. The primary efficacy measure was cumulative pain score with activity through 72 hours postoperatively. Secondary efficacy measures included pain intensity with activity and at rest, postsurgical consumption of rescue opioids, and integrated rank analysis combining pain scores at rest with the amount of opioid used.
[RESULTS] One hundred thirty-six patients were randomized and treated (DepoFoam bupivacaine, n = 66; bupivacaine HCl, n = 70). Reflecting the underpowered nature of the study, the mean cumulative pain score (numeric rating scale with activity through 72 hours) was 441.5 with DepoFoam bupivacaine versus 468.2 with bupivacaine HCl (P = .3999). Total amounts of opioid consumed were significantly lower in the DepoFoam bupivacaine group through 24 hours (P = .0211) and through 48 hours (P = .0459). The prespecified integrated rank analysis showed statistically-significant differences at multiple time points up to and including 60 hours; results on most other efficacy measures trended in favor of DepoFoam bupivacaine. No serious adverse events were reported, and no patients discontinued the study due to adverse events.
[CONCLUSIONS] DepoFoam bupivacaine trended toward benefit versus bupivacaine HCl on most efficacy measures. Due to early termination, the study was underpowered to achieve statistical significance.
[OBJECTIVES] The authors evaluate the extent and duration of analgesia achieved with extended-release DepoFoam bupivacaine (Pacira Pharmaceuticals, Inc., Parsippany, New Jersey) in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty under general anesthesia.
[METHODS] In this randomized, multicenter, double-blind study, patients received a single dose of DepoFoam bupivacaine 600 mg or bupivacaine HCl 200 mg divided into the implant pockets at the conclusion of surgery. The primary efficacy measure was cumulative pain score with activity through 72 hours postoperatively. Secondary efficacy measures included pain intensity with activity and at rest, postsurgical consumption of rescue opioids, and integrated rank analysis combining pain scores at rest with the amount of opioid used.
[RESULTS] One hundred thirty-six patients were randomized and treated (DepoFoam bupivacaine, n = 66; bupivacaine HCl, n = 70). Reflecting the underpowered nature of the study, the mean cumulative pain score (numeric rating scale with activity through 72 hours) was 441.5 with DepoFoam bupivacaine versus 468.2 with bupivacaine HCl (P = .3999). Total amounts of opioid consumed were significantly lower in the DepoFoam bupivacaine group through 24 hours (P = .0211) and through 48 hours (P = .0459). The prespecified integrated rank analysis showed statistically-significant differences at multiple time points up to and including 60 hours; results on most other efficacy measures trended in favor of DepoFoam bupivacaine. No serious adverse events were reported, and no patients discontinued the study due to adverse events.
[CONCLUSIONS] DepoFoam bupivacaine trended toward benefit versus bupivacaine HCl on most efficacy measures. Due to early termination, the study was underpowered to achieve statistical significance.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | mammaplasty
|
유방성형술 | dict | 2 | |
| 기법 | submuscular
|
근막하 평면 | dict | 2 | |
| 시술 | breast augmentation
|
유방성형술 | dict | 1 | |
| 해부 | breast
|
유방 | dict | 1 | |
| 약물 | bupivacaine
|
C0006400
bupivacaine
|
scispacy | 1 | |
| 약물 | extended-release
|
scispacy | 1 | ||
| 약물 | bupivacaine HCl
|
C0887621
bupivacaine hydrochloride
|
scispacy | 1 | |
| 약물 | [BACKGROUND] Breast
|
scispacy | 1 | ||
| 약물 | [OBJECTIVES]
|
scispacy | 1 | ||
| 약물 | Pacira
|
scispacy | 1 | ||
| 약물 | DepoFoam bupivacaine 600
|
scispacy | 1 | ||
| 약물 | [RESULTS] One hundred thirty-six
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] DepoFoam
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | extended-release DepoFoam
|
scispacy | 1 | ||
| 기타 | opioids
|
scispacy | 1 |
MeSH Terms
Adult; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Mammaplasty; Pain Measurement; Postoperative Pain
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.